DEBRA Research and Dermaliq Collaborate to Enhance Drug Delivery for Epidermolysis Bullosa

MUNICH, Germany and WILMINGTON, DE, USA, May 28, 2025 – DEBRA Research gGmbH, a global non-profit organization focused on advancing research and drug development for Epidermolysis Bullosa (EB), has entered into a strategic partnership with Dermaliq Therapeutics, Inc., a clinical-stage company innovating in dermatology with next-generation topical therapies. This collaboration aims to enhance the delivery of drugs directly into the skin to treat EB, starting with efforts to improve therapies for wound healing and itch relief, while also working on preventive treatments for those with EB. As part of this partnership, DEBRA Research has invested in Dermaliq.

Epidermolysis Bullosa is a group of rare genetic disorders that result in extremely fragile skin, causing blisters and wounds from minor friction or trauma. Individuals with EB face numerous daily challenges and the condition can lead to severe complications, including chronic wounds, infections, and internal organ issues. It is caused by gene mutations that affect the proteins responsible for skin integrity. Although there is no cure currently, ongoing research aims to manage symptoms and improve the lives of those affected.

Dermaliq is at the forefront of developing new therapeutic strategies for managing skin conditions and wounds in EB patients. Their proprietary technology, hyliQ®, facilitates the precise delivery of active ingredients into the skin without causing further harm to sensitive or damaged tissue. Designed for conditions such as EB, where the skin is exceptionally vulnerable, this technology allows for touchless application, protecting the skin from further damage while providing effective treatments.

Dr. Christoph Coch, Managing Director at DEBRA Research, stated, "This partnership aligns with our mission to fast-track the development of impactful therapies for individuals with EB. Dermaliq’s technology and clinical developments provide a promising solution to the challenges of current topical treatments, especially for the fragile skin that characterizes EB. We believe this collaboration will be crucial in developing transformative therapies and improving outcomes and quality of life for those affected by this debilitating condition."

Frank Löscher, PhD, CEO of Dermaliq, added, "We are thrilled to collaborate with DEBRA Research to address this urgent medical need. Our partnership highlights our shared dedication to helping those suffering from this condition. Featuring unique attributes and an excellent safety profile, hyliQ® is perfectly designed for the touchless treatment of affected and damaged skin. We are eager to see the positive impact this collaboration will have on the EB community and beyond."

DEBRA Research operates as a non-profit devoted to advancing treatments for EB, a rare and life-limiting genetic disorder. As part of DEBRA Austria, a patient-centered organization founded in 1995, DEBRA Research collaborates on a global scale with academia, biotechnology firms, pharmaceutical companies, patient organizations, and regulatory bodies to foster innovation. The organization concentrates on translational research and clinical development to address the unmet needs of people living with EB, aiming for a future where EB can be cured.

Dermaliq Therapeutics is positioned to revolutionize topical dermatology through its hyliQ® technology platform. By overcoming traditional delivery challenges, this breakthrough enables unprecedented absorption into skin structures, offering enhanced bioavailability and skin compatibility. Dermaliq’s innovations provide opportunities for first-in-class topical treatments with applications across dermatology and rare diseases, contributing to significant growth and value creation in the long term. The company’s development pipeline includes assets for conditions such as androgenetic alopecia, alopecia areata, and wound healing.